

Rydym yn croesawu gohebiaeth yn y Gymraeg neu'r Saesneg. Atebir gohebiaeth Gymraeg yn y Gymraeg, ac ni fydd hyn yn arwain at oedi. We welcome correspondence in Welsh or English. Welsh language correspondence will be replied to in Welsh, and this will not lead to a delay.

Cais Rhyddid Gwybodaeth / Freedom of Information request **Ein Cyf / Our Ref: 23-F-028**

Please note that we have provided this information for the period March to May 2023.

You asked:

1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	We are unable to split Abemaciclib patients – total of 14 patients on all combinations
Abemaciclib + Fulvestrant	
Alpelisib + Fulvestrant	0
Anthracycline (e.g. doxorubicin or epirubicin) as a single agent	<5*
Atezolizumab + Nab-paclitaxel/Paclitaxel	<5*
Capecitabine as a single agent	12
Eribulin as a single agent or in combination	6
Everolimus + Exemestane	<5* patients on Everolimus. Exemestane data is not held centrally so we are unable to provide information on combination
Fulvestrant as a single agent	21 (unable to state if combined with aromatase inhibitors)
Lapatinib	0
Neratinib	0
PARP inhibitors (Olaparib/Talazoparib)	0
Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	Unable to split Palbociclib patients – total of 35 patients on all combinations



Palbociclib + Fulvestrant	
Pembrolizumab	5
Platinum (e.g. carboplatin or cisplatin) as a single agent	7
Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	We are unable to split Ribociclib patients – total of 15 patients on all combinations
Ribociclib + Fulvestrant	
Sacituzumab Govitecan	<5*
Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent	23
Taxane and/or Anthracycline in combination	35
Trastuzumab as a single agent or in combination	21
Trastuzumab emtansine	7
Trastuzumab deruxtecan	5
Any other active systemic anti-cancer therapy	6

* Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

2. Does your health board participate in any clinical trials for the treatment of breast cancer? If so, please provide the name of each trial and the number of patients taking part.

Yes, in the time period specified the health board participated in the following clinical trials for the treatment of breast cancer;

- NOSTRA - A prospective non-randomised, multi-centre feasibility study to assess if patients with residual cancer following dual-targeted neoadjuvant chemotherapy treatment for HER2-positive, ER-negative early breast cancer can be identified by multiple ultrasound-guided tumour bed core biopsies.
- DESTINY09 - Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
- Tropion02 - A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in



Patients who are not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

- HeredERA - PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDISTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO + TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER
- OPTIMA - Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis
- SMR3760 - Phase II, open label, single arm study to investigate anti-tumor effect of ixabepilone in patients with locally recurrent or metastatic breast cancer (mBC) selected by the ixabepilone Drug Response Prediction (DRP) after failure of an anthracycline and a taxane.
- PARTNER - Platinum and PARP inhibitor for Neoadjuvant treatment of Triple Negative and/or BRCA positive breast cancer

A total of 25 patients were recruited across all trials.

